Pfizer, BioNTech Shares Ripe for a Bumpy Ride Ahead of Key Panel – BloombergQuint

(Bloomberg) — Its been a wild ride for Pfizer Inc. shares as the S&P 500 heavyweight got caught up in the vaccine-stock euphoria. A key panel next week could mean even more volatility.
A Food and Drug Administration advisory committee meeting scheduled for Dec. 10 is believed to be a means for the agency to assure the public about Covid-19 vaccine safety, and a U.S. emergency use authorization could follow within days.
Pfizer shares have gained about 20% since late October even after a dip on Thursday,…

Click here to view the original article.